Significant Breakthrough in ADHD Treatment
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical company, recently reported remarkable outcomes from its FOCUS Phase 3 trial focusing on solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. This trial has validated the potential of solriamfetol, highlighting its efficacy in significantly alleviating ADHD symptoms compared to placebo treatments.
Key Findings from the FOCUS Trial
The FOCUS trial was conducted with a large participant base of 516 adults diagnosed with ADHD, divided into groups receiving either solriamfetol at varied dosages or placebo. Notably, the primary endpoint was met with a substantial reduction in ADHD symptoms. After six weeks, individuals taking 150 mg of solriamfetol experienced an average decrease of 17.7 points on the Adult ADHD Investigator Symptom Rating Scale (AISRS), illustrating a mean reduction of 45% from initial baseline scores. In contrast, those on placebo reported only a 14.3-point reduction (p=0.039).
Moreover, a noteworthy finding is that the improvements in ADHD symptoms began as early as Week 1 for those using solriamfetol, indicating a promising onset of action (p=0.036). Additionally, there was a significant rate of clinical response, with 53.5% of patients in the solriamfetol group achieving a clinically meaningful improvement of 30% or more, while only 41.3% in the placebo group could do so (p=0.024).
Measuring Overall Severity of ADHD
The trial also demonstrated strong results in secondary measures, particularly in the Clinical Global Impression of Severity (CGI-S) for ADHD. Statistically significant improvements in disease severity were observed (p=0.017) at the six-week mark, reinforcing the efficacy of solriamfetol as a treatment option for adults living with ADHD.
Despite the positive outcomes, the exploratory analysis for those on the 300 mg dosage of solriamfetol yielded numerically better results compared to placebo, though these were not statistically significant.
Expert Insights on ADHD and Solriamfetol
In commentary about the trial's implications, Dr. Gregory Mattingly emphasized the longstanding challenges presented by ADHD, which can severely affect various aspects of individuals’ lives. He noted, "The results of the FOCUS trial demonstrate that solriamfetol was able to reduce mean ADHD symptom burden by nearly fifty percent, which contributed to significant reductions in disease severity. These results are especially promising as part of a comprehensive wellness plan for individuals with ADHD." He also reaffirmed the favorable safety profile of solriamfetol observed during the trial.
Future Directions for Axsome Therapeutics
Axsome Therapeutics’ CEO, Dr. Herriot Tabuteau, expressed satisfaction with the trial's results, stating that this marks significant progress in the understanding of ADHD treatments. "We look forward to advancing the development of solriamfetol as a new, differentiated potential treatment for the millions of patients living with ADHD. With these results in the adult population in hand, we plan to initiate a trial in pediatric patients this year," he affirmed.
With its demonstrated efficacy and well-tolerated profile, solriamfetol presents a promising new option for those struggling with ADHD—a condition that affects millions of adults across the globe. As Axsome Therapeutics continues its research, the hope is to broaden the availability of effective treatments, ensuring better outcomes and quality of life for those impacted by ADHD.
Frequently Asked Questions
1. What is the FOCUS trial about?
The FOCUS trial evaluated the efficacy and safety of solriamfetol in treating ADHD in adults, demonstrating significant improvements in ADHD symptoms.
2. What were the key findings of the trial?
The trial showed significant reductions in ADHD symptoms and disease severity compared to placebo, with solriamfetol demonstrating a mean reduction of 45% in symptoms.
3. What does solriamfetol do?
Solriamfetol is designed to enhance dopamine and norepinephrine levels, which help improve attention, focus, and impulse control in individuals with ADHD.
4. How was the trial conducted?
The trial involved 516 participants randomized to receive either solriamfetol or placebo over a period of six weeks, ensuring a rigorous assessment of its effects.
5. What are the next steps for Axsome Therapeutics?
Axsome plans to initiate trials with solriamfetol in pediatric patients and continues to explore its wider applicability in treating ADHD.
